Search in:

Scandinavian Journal of Urology and Nephrology Volume 30, 1996 - Issue 4

Submit an article Journal homepage

Views

CrossRef citations to date

Altmetric

Original Paper

The Effect of Buserelin Versus Conventional Antiandrogenic Treatment in Patients with T_2-4N_XM₁ Prostatic Cancer

A Prospective, Randomized Multicentre Phase III Trial

E. Bruun Department of Urology, Gentofte Hospital, University of Copenhagen, Denmark

C. Frimodt-Møller Department of Urology, Gentofte Hospital, University of Copenhagen, Denmark

& Danish Buserelin Study Group

Pages 291-297 | Received 29 Jan 1993, Accepted 03 Aug 1995, Published online: 15 Feb 2010

Cite this article
https://doi.org/10.3109/00365599609182309

References
Citations
Metrics
Reprints & Permissions

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (9)

S. V. Mishugin, A. A. Mordovin & I. G. Rusakov. (2015) Buserelin-long PhC in the treatment of disseminated prostate cancer. Onkologiya. Zhurnal imeni P.A.Gertsena 4:3, pages 24.
Crossref

Frank Kunath, Henrik R Grobe, Gerta Rücker, Edith Motschall, Gerd Antes, Philipp Dahm, Bernd Wullich & Joerg J Meerpohl. (2014) Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database of Systematic Reviews.
Crossref

Santiago Vilar González & Xavier Maldonado Pijuan. (2011) Evidence-based medicine: comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate. BJU International 107:8, pages 1200-1208.
Crossref

Malcolm Mason. (2006) What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?. Journal of Cancer Research and Clinical Oncology 132:S1, pages 27-35.
Crossref

Laurent Boccon-Gibod. (2005) Optimising Hormone Therapy in Advanced Disease. European Urology Supplements 4:8, pages 21-29.
Crossref

P. Mongiat-Artus & P. Teillac. (2005) Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate Cancer. European Urology Supplements 4:5, pages 4-13.
Crossref

Christopher P. Evans, Neil Fleshner, John M. Fitzpatrick & Alexander R. Zlotta. (2005) An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases. BJU International 95:6, pages 743-749.
Crossref

Jerome SeidenfeldDavid J. SamsonVic HasselbladNaomi AronsonPeter C. AlbertsenCharles L. BennettTimothy J. Wilt. (2000) Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer. Annals of Internal Medicine 132:7, pages 566.
Crossref

G. Höfling & H. Heynemann. (2014) Die orale Östrogentherapie des fortgeschrittenen Prostatakarzinoms — Anlaß für eine Neubewertung?. Der Urologe B 38:2, pages 165-170.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

The Effect of Buserelin Versus Conventional Antiandrogenic Treatment in Patients with T_2-4N_XM₁ Prostatic Cancer

A Prospective, Randomized Multicentre Phase III Trial

Articles from other publishers (9)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The Effect of Buserelin Versus Conventional Antiandrogenic Treatment in Patients with T2-4NXM1 Prostatic Cancer

A Prospective, Randomized Multicentre Phase III Trial

Citations (9)

Articles from other publishers (9)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

The Effect of Buserelin Versus Conventional Antiandrogenic Treatment in Patients with T_2-4N_XM₁ Prostatic Cancer